Previous 10 | Next 10 |
COPENHAGEN, Denmark, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that the Company’...
2024-01-22 12:31:12 ET Gainers: Sagimet Biosciences ( SGMT ) +106% . Rail Vision Ltd ( RVSN ) +51% . Digital World Acquisition Corp ( DWAC ) +49% . Bullfrog AI Holdings ( BFRG ) +38% . CXApp ( CXAI ) +34% . Phunware ( PHUN ...
2024-01-22 08:02:10 ET Evaxion Biotech A/S (EVAX) announced stock split at a ratio of 1-for-10 on 2024-01-22 ... Full story available on KlickAnalytics.com
2024-01-08 08:43:06 ET More on Evaxion Biotech ADS Evaxion Biotech to raise $5.3M via private placement Evaxion stock rallies 16% on early Phase 2 results for cancer vaccine Seeking Alpha’s Quant Rating on Evaxion Biotech ADS For further details see: ...
COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change...
MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering ...
Christian Kanstrup joined Evaxion as Chief Executive Officer in September Evaxion has launched its refined strategy with an increased focus on value realization via partnerships based upon the AI-Immunology™ platform Solid progress has already been seen on the refined strategy with...
2023-12-19 09:48:08 ET More on Evaxion Biotech ADS Evaxion stock rallies 16% on early Phase 2 results for cancer vaccine Seeking Alpha’s Quant Rating on Evaxion Biotech ADS Historical earnings data for Evaxion Biotech ADS Financial information for Evax...
MSD Global Health Innovation Fund (MSD GHI), a corporate venture capital arm of Merck & Co., Inc., Rahway, NJ, USA, is contributing with some 25% of the total offering amount Company’s management and board of directors with significant participation in the total offering ...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...